Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
Authors:
- Marcin OkrojMOMarcin Okroj
- Anders ÖsterborgAÖAnders Österborg
- Anna M. BlomABAnna M. Blom
- 1 October 2013
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 39 (6) , 632-639
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic LeukemiaClinical Cancer Research, 2011
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- CD20 deficiency in humans results in impaired T cell–independent antibody responsesJournal of Clinical Investigation, 2010
- Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo modelBlood, 2009
- Anti-CD20 monoclonal antibodies: historical and future perspectivesHaematologica, 2009
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyBlood, 2009
- Modulation of the antitumor immune response by complementNature Immunology, 2008
- NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complementBlood, 2008
- Complement activation and cytokine response by BioProtein, a bacterial single cell proteinClinical and Experimental Immunology, 2007
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximabBlood, 2006